CN100518810C - Chinese medicinal composition for treating gastroesophageal reflux disease - Google Patents
Chinese medicinal composition for treating gastroesophageal reflux disease Download PDFInfo
- Publication number
- CN100518810C CN100518810C CNB2007100173496A CN200710017349A CN100518810C CN 100518810 C CN100518810 C CN 100518810C CN B2007100173496 A CNB2007100173496 A CN B2007100173496A CN 200710017349 A CN200710017349 A CN 200710017349A CN 100518810 C CN100518810 C CN 100518810C
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- treatment
- gastroesophageal reflux
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 208000021302 gastroesophageal reflux disease Diseases 0.000 title claims description 47
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims description 62
- 238000011282 treatment Methods 0.000 claims description 49
- 229940079593 drug Drugs 0.000 claims description 21
- 241000407170 Curcuma Species 0.000 claims description 15
- 241000207929 Scutellaria Species 0.000 claims description 15
- 241000218176 Corydalis Species 0.000 claims description 4
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 241000545442 Radix Species 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 241000555682 Forsythia x intermedia Species 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 7
- 241001647745 Banksia Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241001522129 Pinellia Species 0.000 abstract 1
- 241000220317 Rosa Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 27
- 210000003238 esophagus Anatomy 0.000 description 23
- 230000000694 effects Effects 0.000 description 12
- 210000004400 mucous membrane Anatomy 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 206010067171 Regurgitation Diseases 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 9
- 239000003390 Chinese drug Substances 0.000 description 8
- 201000006549 dyspepsia Diseases 0.000 description 8
- 208000024798 heartburn Diseases 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 238000001839 endoscopy Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 208000023514 Barrett esophagus Diseases 0.000 description 6
- 208000023665 Barrett oesophagus Diseases 0.000 description 6
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 6
- 206010058314 Dysplasia Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 230000001174 ascending effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000002580 esophageal motility study Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 230000000630 rising effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229940069428 antacid Drugs 0.000 description 4
- 239000003159 antacid agent Substances 0.000 description 4
- 230000001458 anti-acid effect Effects 0.000 description 4
- 230000000151 anti-reflux effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000002575 gastroscopy Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000007119 pathological manifestation Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 206010070245 Foreign body Diseases 0.000 description 2
- 241000555712 Forsythia Species 0.000 description 2
- 208000031361 Hiccup Diseases 0.000 description 2
- 206010030094 Odynophagia Diseases 0.000 description 2
- 206010030216 Oesophagitis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 208000006881 esophagitis Diseases 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 208000000689 peptic esophagitis Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010049235 Nocturnal dyspnoea Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000006766 bile reflux Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 230000002182 neurohumoral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000004514 sphincter of oddi Anatomy 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a Chinese medicinal composition for treating stomach and gullet reverse-current disease, wherein the preparation is prepared from the following raw materials (by weight portion): bupleurum root 5-15 parts, white peony root 10-20 parts, bitter orange 5-15 parts, pinellia tuber 5-15 parts, dried orange peel 5-15 parts, cuttle-bone 10-20 parts, baikal skullcap root 5-15 parts, curcuma root 5-15 parts, banksia rose 2-8 parts and licorice 2-8 parts.
Description
Technical field
The invention belongs to technical field of Chinese medicines, relate to a kind of Chinese medicine composition that is used for the treatment of gastroesophageal reflux disease.
Background technology
Gastroesophageal reflux disease (Gastroesophageal reflux disease, GERD) be meant gastric content counter flow into esophagus cause malaise symptoms and (or) a kind of disease of complication.GERD can be divided into non-erosive reflux disease (Nonerosive esophageal reflux disease, NERD), reflux esophagitis (Reflux esophagitis, RE) and the Barrett esophagus (Barrett ' s esophagus, BE) three types.GERD is more common in western countries, it is reported, has 44% people that anti-stream symptom was arranged 1 time at least in every month among the American, and 20% people has anti-stream symptom at least weekly 1 time.Abroad the report to the GERD prevalence is generally 7%～15%, also has up to more than 20%.In recent years Chinese scholar shows that to Beijing and two places, Shanghai survey result the prevalence of GERD is 5.77%.
Gastroesophageal reflux disease is a kind of commonly encountered diseases, and classical symptom is burn feeling behind stomach or the breastbone, acid regurgitation, can merge diseases such as cough, asthma, pharyngolaryngitis and nocturnal dyspnea, has a strong impact on patient's health and quality.Its pathogenesis mainly is the result that the anti-reflux defense mechanism of esophagus descends and anti-stream thing damages mucous membrane of esophagus that multiple factor causes.Normal lower esophageal sphincter (LES) has anti-reflux barrier function.Not normal as the neuro humor adjusting, food, medicine or intra-abdominal pressure, gastric are pressed and are increased, and all can influence LES and press corresponding reduction, or a mistake property LES is lax, and cause gastroesophageal reflux.Anti-stream thing enters esophagus, and the sour scavenging action of esophagus is weakened, and anti-gastric acid, pepsin or cholic acid, the pancreatin etc. that flow in the thing all can damage mucous membrane of esophagus, and esophagus is inflamed; And the secondary esophageal peristalsis that is inflamed weakens, and the anti-thing that flows can not in time be removed, and increases the weight of esophagitis again, causes vicious cycle.RE takes place in the GERD patient of about half.Esophagitis shows effect repeatedly, makes proliferation of fibrous tissue, can cause cicatricial stricture.In the mucous membrane of esophagus repair process, squamous epithelial cancer is replaced by columnar epithelium, is referred to as the Barrett esophagus, is precancerous lesion.The traditional Chinese medical science thinks, the generation of primary disease mainly is the elevating function imbalance of taste, and deficiency of spleen-QI is clear QI failing to ascend then, and disorder of stomach-QI is turbid QI failing to descend then, superinverse and anti-stream.And the lifting of taste is regulated by the mechanism of qi of liver controlling conveyance and dispersion, stagnation of QI due to depression of the liver, and catharsis dereliction of duty, perverse and unreasonable manner is violated stomach, influences the lifting of taste, adverse rising of stomach-QI and form anti-stream.So the liver failing to maintain the normal flow of QI is the major reason of adverse rising of stomach-QI.With stagnation of liver-QI with deficiency of the spleen, adverse rising of stomach-QI is more to be seen clinically.The western medical treatment gastroesophageal reflux disease based on the gastric acid inhibitory secretion, comprises H at present
2Receptor antagonist (H
2And the curative effect of PPI is better than H RA) and proton pump inhibitor (PPI),
2RA, effective percentage 60%～70%.But primary disease has chronic tendency of recurrence, report drug withdrawal relapse rate later six months is arranged up to 70%～80%, so need long term maintence therapy.Medical treatment is invalid maybe can not adhere to long-term pill taker, can adopt anti-reflux operative treatments such as fundoplication, but postoperative has quite a few patient (11%～60%) still to need regular medication.Severe dysplasia or the early stage esophageal carcinoma, in time excision are arranged.And the clinical report of relevant Chinese medicine systematic treating primary disease is less.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease.
The present invention treats the Chinese medicine composition of gastroesophageal reflux disease, is the preparation that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes,
10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae.
When clinical symptoms shows as heartburnly very the time, on the basis of above-mentioned prescription, add 5～15 parts of Fructus Forsythiaes, 5～15 parts of Radix Paeoniae Rubra.
When clinical symptoms shows as the acid regurgitation weight, on the basis of above-mentioned prescription, add 5～15 parts of Concha Arcae (calcined), 5～15 parts of Bulbus Fritillariae Thunbergiis.
When clinical symptoms shows as the stomachache play, on the basis of above-mentioned prescription, add 5～15 parts of Rhizoma Corydalis, 5～15 parts of the Radixs Angelicae Dahuricae.
When under the scope when mucous membrane of esophagus erosion, ulcer, can on the basis of above-mentioned prescription, add 5～15 parts of Pseudobulbus Bletillae (Rhizoma Bletillae).
When mucous membrane of esophagus edema under the scope, when oozing out, can on the basis of above-mentioned prescription, add 5～15 parts of the Rhizoma Atractylodis Macrocephalaes, 10～20 parts in Poria.
When endoscopy and pathological manifestations are dysplasia or Barrett esophagus, on the basis of above-mentioned prescription, add 5～15 parts of Rhizoma Curcumae, 10～20 parts of Radix Salviae Miltiorrhizaes, 20～40 parts of Semen Coiciss.
The pathogenesis of gastroesophageal reflux disease is stagnation of liver-QI with deficiency of the spleen, adverse rising of stomach-QI, and medicine of the present invention is intended the dispersing the stagnated liver-QI for regulating the stomach sending down the abnormal ascending QI, and pathogenesis hits.The soothing the liver reason spleen of Sini San in the medicine of the present invention; The Rhizoma Pinelliae, Pericarpium Citri Reticulatae regulating the stomach and sending down the abnormal ascending QI; Radix Scutellariae is joined Rhizoma Pinelliae pungent drugs can disperse and bitter drugs can descend; The Radix Aucklandiae, Radix Curcumae promoting flow of QI and blood; Infections is held back in Os Sepiae antacid, altogether the merit of long memorial liver reason spleen, antacid circulation of qi promoting, regulating the stomach and sending down the abnormal ascending QI.
The modern pharmacology result of study shows that in the medicine of the present invention, Radix Bupleuri, the Radix Paeoniae Alba, Fructus Aurantii, Pericarpium Citri Reticulatae, the Radix Aucklandiae, Radix Curcumae, the Rhizoma Pinelliae, Radix Glycyrrhizae have and regulate the two-way function that gastrointestinal smooth muscle is excited and suppress; Radix Bupleuri, the Radix Paeoniae Alba, Fructus Aurantii, Radix Glycyrrhizae, Radix Curcumae, Pericarpium Citri Reticulatae, Radix Scutellariae have function of gallbladder promoting, hepatoprotective effect, and wherein the collapsible gallbladder of Fructus Aurantii increases Oddi's sphincter tension force, so that fundamentally suppresses gastric reflux and bile reflux; Os Sepiae, Radix Bupleuri, the Radix Paeoniae Alba, Radix Glycyrrhizae antacid, antiulcer; Radix Bupleuri, Radix Scutellariae, the Radix Paeoniae Alba, Pericarpium Citri Reticulatae, the Radix Aucklandiae, Radix Curcumae, Radix Glycyrrhizae are antibacterial, antiinflammatory; The effect of protection mucous membrane of esophagus, relief of symptoms is gathered in Radix Bupleuri, the Radix Paeoniae Alba, Radix Curcumae analgesia altogether.
Chinese medicine is soothing the liver reason spleen, regulating the stomach and sending down the abnormal ascending QI has the neurohumoral function of adjusting, strengthens the anti-reflux defense mechanism of esophagus and to the removing of anti-stream thing, plays permanent curing action; The while vital energy regualting and blood circulation-promoting, infections is held back in antacid, lowers the infringement and the protection mucous membrane of esophagus of anti-stream thing, improves the diseased region blood circulation, helps the reparation of mucous membrane of esophagus, plays the effect of taking stopgap measures.Analysis on Mechanism from treatment can obviously embody the advantage of Chinese medicine, so can obtain satisfied curative effect.
Chinese medicine composition of the present invention can be proved absolutely by following clinical trial the therapeutic effect of gastroesophageal reflux disease.
1, clinical trial data and method
1.1 physical data 70 routine cases are all from JIUYUE, 2005～2006 year outpatient service of JIUYUE No.1 Hospital of Lanzhou University or inpatient.Be divided into 2 groups at random, Chinese drug-treated group 40 examples, matched group 30 examples.Wherein, male 38 examples, women 32 examples, 21～62 years old age, the course of disease 6 months～5 years, average 24.3 months.According to following diagnostic criteria, Chinese drug-treated group patient NERD19 example, RE21 example; Matched group patient NERD14 example, the RE16 example.Two groups of physical data relatively, difference does not have significance meaning (P〉0.05), has comparability.Other has BE patient's 3 examples, because case very little, excludes this group statistical analysis.
1.2 Western medicine diagnose standard
Diagnostic criteria with reference to Sanya gastroesophageal reflux disease common recognition in 2006 and the national anti-fluidity esophagel disease seminar formulation in August, 1999 Yantai.Diagnosis basis:
(1) significantly anti-stream symptom is arranged: with heartburn, acid regurgitation is classical symptom, and related symptoms comprises upper abdominal pain, chest pain, belch, epigastric discomfort, foreign body in pharynx sense, odynophagia, dysphagia etc., and the outer symptom cough of esophagus, laryngitis, asthma etc.
(2) endoscopy: gastroscopy has the breakage of esophagus section far away mucosa, can be diagnosed as RE in conjunction with (1).The biopsy of endoscopy binding of pathological can be diagnosed as BE if there is the squamous epithelial cancer of esophagus section far away to be replaced by columnar epithelium in conjunction with (1).Negative and the person that has the classical symptom of endoscopy can intend examining and is to make a definite diagnosis NERD in conjunction with one of following (3) or (4).
(3) 24h esophageal pH monitoring: normal pH5.5～7.0.As the SI positive, can make a definite diagnosis.Heartburn number of times/heartburn outbreak total degree that the anti-stream of SI=acid (pH＜4) is relevant,〉50% positive.
(4) esophageal manometry: the LES rest pressure is 10～30mmHg.As LES pressure＜6mmHg, can make a definite diagnosis.
1.3 " the new Chinese medicine clinical research guideline " that Chinese medical discrimination was developed and published with reference to health ministry in 1993.Taking place frequently property or persistence gastral cavilty portion causalgia, especially with after the meal for very, acid regurgitation is noisy, the singultus belch, nausea and vomiting, gastral cavilty distending pain or pain are scurried two sides of body, the foreign body in pharynx sense is easily sent out because of feelings will, or inappetence, light red tongue, white and thin fur or little Huang, stringy pulse.Card belongs to hyperactive liver-QI attacking the stomach, adverse rising of stomach-QI.
The mild symptoms weight classification sees the following form:
| Symptom | Gently (+) | In (++) | Heavy (+++) |
| Acid regurgitation, heartburn | Be less than 3 hours every day | At 3-6 hour every day | Noisy all day, acid regurgitation |
| Belch | Be less than every day 5 times | Every day 5-9 time | Every day is more than 10 times |
| Side of body abdominal pain | Often have | Take place frequently, influence work | All day endlessly, influence work and rest |
| Gastral cavity abdominal distention is vexed | The food back occurs | Every day is more than 6 hours | All day |
| Inappetence | Appetite reduces below 1/3 | Appetite reduces 1/2-1/3 | Appetite reduces more than 1/2 |
| Pharyngeal discomfort | Foreign body sensation | Odynophagia | Dysphagia |
1.4 case is selected
1.4.1 standard of including in: meet Western medicine diagnose standard and Chinese medical discrimination person, can include the test case in.
1.4.2 get rid of the case standard:
(1) age is at under-18s or over-65s, gestation or women breast-feeding their children.(2) be associated with stomach, duodenal ulcer, the chronic gastritis severe dysplasia is suspected to have the person of cancerating.(3) esophagus and stomach malignancy patient.(4) merge serious primary disease such as cardiovascular and cerebrovascular vessel, Liver and kidney and hemopoietic system, psychotic.(5) do not meet the standard of including in, not medication and inspection in accordance with regulations, or data is incomplete, and curative effect or safety evaluatio person are judged in influence.
1.5 Therapeutic Method
Two groups of patients all avoid tobacco and wine, strong tea, coffee, chocolate at period in a medicine, and the greasy food that avoids pungent food, diet are based on light, and regulating spirit and emotion by oneself is avoided satiety food and drink or flat immediately after the meal crouching, and can raise the head of a bed 15～20cm during sleep.
Chinese drug-treated group: Radix Bupleuri 10g, Radix Paeoniae Alba 15g, Fructus Aurantii 10g, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 10g, Pericarpium Citri Reticulatae 10g, Os Sepiae 15g, Radix Scutellariae 10g, Radix Curcumae 10g, Radix Aucklandiae 5g, Radix Glycyrrhizae 5g, decocting, divides 2 times decoction being taken warmly at 1 dose of every day.
Clinical symptoms is very heartburn, adds Fructus Forsythiae 10g, Radix Paeoniae Rubra 10g on the basis of above-mentioned prescription.
The clinical symptoms acid regurgitation is heavy, adds Concha Arcae (calcined) 10g, Bulbus Fritillariae Thunbergii 10g on the basis of above-mentioned prescription.
Clinical symptoms stomachache is acute, adds Rhizoma Corydalis 10g, Radix Angelicae Dahuricae 10g on the basis of above-mentioned prescription.
Mucous membrane of esophagus erosion, ulcer under the scope add Pseudobulbus Bletillae (Rhizoma Bletillae) 10g on the basis of above-mentioned prescription.
Mucous membrane of esophagus edema under the scope, ooze out, on the basis of above-mentioned prescription, add Rhizoma Atractylodis Macrocephalae 10g, Poria 15g.
Endoscopy and pathological manifestations are dysplasia or Barrett esophagus, add Rhizoma Curcumae 10g, Radix Salviae Miltiorrhizae 15g, Semen Coicis 30g on the basis of above-mentioned prescription.
More than the equal decocting of prescription, divides 2 times decoction being taken warmly at 1 dose of every day.4 weeks were a course of treatment.
Matched group: oral omeprazole, each 20mg, every day 2 times.4 weeks were a course of treatment.
1.6 observation index
1.6.1 health giving quality observation
(1) clinical symptoms write down respectively 1 time before treatment and in the therapeutic process in per 3 days, by do not have, light, in, heavy level Four record statistics.
(2) electronic gastroscopy and biological tissue pathologic finding.Inspection record respectively before the treatment and after treatment 1 course of treatment.
(3) the 24h esophageal pH detects.Each inspection record is 1 time before and after the treatment.
(4) esophageal manometry.Each inspection record is 1 time before and after the treatment.
1.6.2 safety observation
(1) general health check-up project.Note age, body weight, smoking history, history of drinking history, medication history, gastrointestinal medical history.
(2) blood, urine, stool routine chemical examination.
(3) liver function, the chemical examination of kidney merit, HBSAg, Hp check.
(4) electrocardiogram, liver, gallbladder ultrasound diagnosis.
More than at treatment forward and backward each inspection record 1 time.
1.7 all The data χ of statistical method
2Check.
2, result
2.1 curative effect determinate standard is formulated with reference to " internal disease diagnostic criteria ".
(1) clinical recovery: clinical symptom disappearance, the healing of gastroscope check mucosa pathological changes, the biological tissue pathologic finding confirms that the pathological changes recovery is normal or disappears; Or 24h esophageal pH detection SI feminine gender, esophageal manometry LES presses and recovers normal.
(2) produce effects: clinical cardinal symptom disappears, or acid regurgitation, heartburn disappearance, other sxs, and gastroscope check mucosa diseased region inflammation disappears substantially, and the check of biological tissue pathology confirms that pathological changes obviously alleviates; Or 24h esophageal pH detection SI feminine gender, esophageal manometry LES presses and recovers normal.
(3) effective: clinical cardinal symptom alleviates, and gastroscope check mucosa pathological changes area dwindles more than 1/2, and the biological tissue pathologic finding confirms that pathological changes alleviates.Or the 24h esophageal pH detects SI and esophageal manometry LES is pressed with improvement.
(4) invalid: clinical symptoms and objective determination do not have and improve or anti-deterioration person.
2.2 therapeutic outcome
2.2.1 clinical symptoms improvement situation relatively sees Table 1 before and after the treatment.
The treatment by Chinese herbs group all is better than matched group to the improvement of symptoms such as anti-stream, heartburn, singultus belch, side of body abdominal pain, gastral cavity abdominal distention is vexed, and difference has statistical significance (P＜0.05 or P＜0.01).
Cardinal symptom improvement situation compares [example (%)] before and after the table 1 liang group treatment
Annotate: with comparison after the treatment of control group,
*P＜0.05,
*P＜0.01
2.2.2 two groups of NERD patient's curative effects relatively see Table 2.
Chinese drug-treated group treatment NERD patient's cure rate is 63.2%, and total effective rate is 100%, is better than western medicine group (P＜0.05).
Table 2 liang group NERD patient curative effect is [example (%)] relatively
Annotate: compare with matched group,
*P＜0.05
2.2.3 the gastroscopy situation relatively sees Table 3 before and after the treatment.
Endoscopy has esophagus section far away mucosa injury person 21 examples, matched group 16 examples before the Chinese drug-treated group treatment; Treatment back Chinese drug-treated group total effective rate 85.7% is better than matched group (P＜0.05).
The gastroscopy situation compares (example) before and after table 3 treatment
Annotate: compare with matched group,
*P＜0.05
2.2.4 two groups of therapeutic outcomes relatively see Table 4.
The total effective rate of Chinese drug-treated group and matched group is respectively 92.5% and 63.3%, and the two is compared, and difference has statistical significance (P＜0.05).
Table 4 liang group therapeutic outcome is (example) relatively
Annotate: compare with matched group,
*P＜0.05
2.3 toxic and side effects is in observed case, chemical examination liver function, kidney merit, blood, urine, stool routine are all normal, do not find obvious toxic-side effects in the whole treatment by Chinese herbs process.
Medicine of the present invention is treated GERD patient's 40 examples from intending dispersing the stagnated liver-QI for regulating the stomach sending down the abnormal ascending QI soup, and compares with the PPI omeprazole.The result shows that the total effective rate of Chinese drug-treated group reaches 92.5%, and its total effective rate, gastroscope improve effective percentage and to the improvement of cardinal symptom, all obviously be better than matched group.Particularly the effective percentage to NERD patient reaches 100%, cure rate 63.2%.Therefore, Chinese medicine composition of the present invention is evident in efficacy to gastroesophageal reflux disease, and be better than of the treatment of present clinical doctor trained in Western medicine, and have no side effect based on gastric acid inhibitory, be the ideal medicament of a kind of GERD of treatment, be worthy of popularization.
The specific embodiment
Embodiment 1, a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease are the preparations that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes,
10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae.
This medicine is applicable to the treatment of general gastroesophageal reflux disease.
Embodiment 2, a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease are the preparations that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes,
10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae,
5～15 parts of Fructus Forsythiaes, 5～15 parts of Radix Paeoniae Rubra.
This medicine is applicable to the treatment of the heartburn gastroesophageal reflux disease very of clinical manifestation
Embodiment 3, a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease are the preparations that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes,
10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae,
5～15 parts of Concha Arcae (calcined), 5～15 parts of Bulbus Fritillariae Thunbergiis.
This medicine is applicable to the treatment of the gastroesophageal reflux disease that the clinical manifestation acid regurgitation is heavy.
Embodiment 4, a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease are the preparations that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes,
10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae,
5～15 parts of Rhizoma Corydalis, 5～15 parts of the Radixs Angelicae Dahuricae.
This medicine is applicable to the treatment of the gastroesophageal reflux disease that clinical manifestation stomachache is acute.
Embodiment 5, a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease are the preparations that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes,
10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae,
5～15 parts of Pseudobulbus Bletillae (Rhizoma Bletillae).
The treatment of the gastroesophageal reflux disease when this medicine is applicable to mucous membrane of esophagus erosion, ulcer under the scope.
Embodiment 6, a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease are the preparations that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes,
10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae,
5～15 parts of the Rhizoma Atractylodis Macrocephalaes, 10～20 parts in Poria.
The treatment of the gastroesophageal reflux disease that this medicine is applicable to mucous membrane of esophagus edema under the scope, ooze out.
Embodiment 7, a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease are the preparations that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes,
10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae,
5～15 parts of Rhizoma Curcumae, 10～20 parts of Radix Salviae Miltiorrhizaes, 20～40 parts of Semen Coiciss.
This medicine is applicable to that endoscopy and pathological manifestations are the treatment of the gastroesophageal reflux disease of dysplasia or Barrett esophagus.
Claims (7)
1, a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease is the oral formulations that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes, 10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae.
2, a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease is the preparation that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes, 10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae, 5～15 parts of Fructus Forsythiaes, 5～15 parts of Radix Paeoniae Rubra.
3, a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease is the preparation that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes, 10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae, 5～15 parts of Concha Arcae (calcined), 5～15 parts of Bulbus Fritillariae Thunbergiis.
4, a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease is the preparation that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes, 10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae, 5～15 parts of Rhizoma Corydalis, 5～15 parts of the Radixs Angelicae Dahuricae.
5, a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease is the preparation that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes, 10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae, 5～15 parts of Pseudobulbus Bletillae (Rhizoma Bletillae).
6, a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease is the preparation that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes, 10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae, 5～15 parts of the Rhizoma Atractylodis Macrocephalaes, 10～20 parts in Poria.
7, a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease is the preparation that is prepared from by following bulk drugs:
5～15 parts of Radix Bupleuri, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Fructus Aurantiis, 5～15 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s, 5～15 parts of Pericarpium Citri Reticulataes, 10～20 parts of Os Sepiae, 5～15 parts of Radix Scutellariaes, 5～15 parts of Radix Curcumaes, 2～8 parts of the Radix Aucklandiae, 2～8 parts of Radix Glycyrrhizae, 5～15 parts of Rhizoma Curcumae, 10～20 parts of Radix Salviae Miltiorrhizaes, 20～40 parts of Semen Coiciss.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100173496A CN100518810C (en) | 2007-01-24 | 2007-01-24 | Chinese medicinal composition for treating gastroesophageal reflux disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100173496A CN100518810C (en) | 2007-01-24 | 2007-01-24 | Chinese medicinal composition for treating gastroesophageal reflux disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101011557A CN101011557A (en) | 2007-08-08 |
| CN100518810C true CN100518810C (en) | 2009-07-29 |
Family
ID=38699397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2007100173496A Expired - Fee Related CN100518810C (en) | 2007-01-24 | 2007-01-24 | Chinese medicinal composition for treating gastroesophageal reflux disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100518810C (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757601B (en) * | 2010-04-07 | 2011-03-23 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composite for treating esophageal rheumatism and preparation method thereof |
| CN102861199A (en) * | 2011-07-04 | 2013-01-09 | 中国中医科学院西苑医院 | Traditional Chinese medicine composition for treating gastroesophageal reflux disease and preparation method |
| CN102406918A (en) * | 2011-11-30 | 2012-04-11 | 宋爱民 | Traditional Chinese preparation for treating nervous vomiting |
| CN103301389A (en) * | 2012-03-06 | 2013-09-18 | 郑治敬 | Prescription for treating intractable stomach trouble |
| CN102600433A (en) * | 2012-03-31 | 2012-07-25 | 王海燕 | Traditional Chinese medicine combination for curing gastro-esophageal reflux disease |
| CN102813824B (en) * | 2012-08-18 | 2013-08-21 | 白石根 | Medicament for treating gastropathy |
| CN102885978B (en) * | 2012-09-29 | 2014-06-18 | 姜相君 | Medicine for treating gastroesophageal reflux and preparation method thereof |
| CN103393806B (en) * | 2013-07-29 | 2014-09-24 | 蔡红艳 | Traditional Chinese medicine for treating spleen-deficiency and qi stagnation-type reflux esophagitis |
| CN105749156B (en) * | 2016-03-11 | 2019-11-05 | 沈宁 | A kind of Chinese medicine composition and preparation method thereof for treating syndrome of dampness-heat stagnating in spleen |
| CN107362331B (en) * | 2017-07-28 | 2020-10-27 | 北京小汤山医院 | Traditional Chinese medicine composition and preparation method and application thereof |
| CN107929546A (en) * | 2017-12-19 | 2018-04-20 | 申艳慧 | A kind of left gold presses down anti-Chinese medicine composition and preparation method and application |
| CN109846996B (en) * | 2019-02-15 | 2021-09-17 | 新乡医学院第一附属医院(河南省结核病医院) | Bletilla striata and mixed agent combined nystatin tablets for treating candida esophagitis |
| CN112316085A (en) * | 2020-11-15 | 2021-02-05 | 石门县中医医院 | Radix bupleuri liver soothing powder medicine composition for treating gastrointestinal hemorrhage and application thereof |
| CN114848735A (en) * | 2022-04-26 | 2022-08-05 | 中环国际知识产权服务(包头)有限公司 | Traditional Chinese medicine composition and preparation method thereof |
-
2007
- 2007-01-24 CN CNB2007100173496A patent/CN100518810C/en not_active Expired - Fee Related
Non-Patent Citations (14)
| Title |
|---|
| 中医药治疗胃食管反流病述要. 杨雯轩等.实用中医内科杂志，第19卷第6期. 2005 |
| 中医药治疗胃食管反流病述要. 杨雯轩等.实用中医内科杂志，第19卷第6期. 2005 * |
| 反流性食管炎的中医辨证治疗. 张莹雯.医学新知杂志，第14卷第4期. 2004 |
| 反流性食管炎的中医辨证治疗. 张莹雯.医学新知杂志，第14卷第4期. 2004 * |
| 承伯钢辨治胃食管反流病的经验. 邓聪等.四川中医，第24卷第6期. 2006 |
| 承伯钢辨治胃食管反流病的经验. 邓聪等.四川中医，第24卷第6期. 2006 * |
| 胃食管反流病从气机论治探析. 潘霜等.时珍国医国药，第17卷第4期. 2006 |
| 胃食管反流病从气机论治探析. 潘霜等.时珍国医国药，第17卷第4期. 2006 * |
| 胃食管反流病的中医治疗近况. 纪延龙.山东中医杂志，第23卷第7期. 2004 |
| 胃食管反流病的中医治疗近况. 纪延龙.山东中医杂志，第23卷第7期. 2004 * |
| 调升降治脾胃病. 任爱萍.河南中医，第25卷第6期. 2005 |
| 调升降治脾胃病. 任爱萍.河南中医，第25卷第6期. 2005 * |
| 赵健雄教授用方经验举隅. 张子理.甘肃中医学院学报，第17卷第1期. 2000 |
| 赵健雄教授用方经验举隅. 张子理.甘肃中医学院学报，第17卷第1期. 2000 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101011557A (en) | 2007-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100518810C (en) | Chinese medicinal composition for treating gastroesophageal reflux disease | |
| CN102166284B (en) | Medicine for treating reflux esophagitis and preparation method thereof | |
| CN110193073A (en) | A kind of Traditional Chinese medicine compound composition that treating atrophic gastritis and gastric precancerous lesion and its application | |
| CN101209340B (en) | Chinese medicinal composition for treating gastroesophageal reflux disease | |
| CN103751739A (en) | Traditional Chinese medicine composition for treating chronic gastritis, application of composition in preparation of medicine for treating chronic gastritis, and preparation method of composition | |
| CN115487258A (en) | Traditional Chinese medicine composition for treating gastroesophageal reflux disease, traditional Chinese medicine preparation and preparation method | |
| CN102813711B (en) | Medicine for treating gastroesophageal reflux disease and application of medicine | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN104306941B (en) | A kind of medicine for treating Non-erosive gastroesophageal reflux disease and its application | |
| CN104906554B (en) | A kind of Chinese medicine composition for treating refractory gastroesophageal reflux disease and its application | |
| CN104547560A (en) | Medicine for treating gastric diseases and preparation method thereof | |
| CN114632130A (en) | Traditional Chinese medicine composition for treating metaplasia atrophic gastritis | |
| CN103316175A (en) | Traditional Chinese medicine powder, and preparation method and application thereof | |
| CN105148151A (en) | Medicine for treating spleen and stomach deficiency-cold type reflux esophagitis and preparation method | |
| CN104784650A (en) | Pharmaceutical preparation for clinical nursing of gastric ulcer | |
| CN116747274B (en) | Traditional Chinese medicine composition and preparation for treating gastroesophageal reflux disease with syndrome of liver-stomach stagnation heat and application of traditional Chinese medicine composition and preparation | |
| CN102512643B (en) | Traditional Chinese medicine composition for treating GERD (gastroesophageal reflux disease) and FGID (functional gastrointestinal disorders) | |
| CN104815278B (en) | Peaceful tea composition of stomach and preparation method thereof | |
| CN103191345B (en) | Postoperative drug for chronic peptic ulcer and esophagitis syndrome | |
| CN116832113B (en) | Traditional Chinese medicine composition and traditional Chinese medicine decoction for treating gastroesophageal reflux disease, and preparation method and application thereof | |
| CN110038113B (en) | Traditional Chinese medicine composition and medicine for gastroesophageal reflux disease, and preparation method and application thereof | |
| CN116603023B (en) | Traditional Chinese medicine composition for treating gastroesophageal reflux disease and application thereof | |
| CN107929546A (en) | A kind of left gold presses down anti-Chinese medicine composition and preparation method and application | |
| CN116350741B (en) | Traditional Chinese medicine composition for treating diabetic gastroparesis and preparation method thereof | |
| CN102327474A (en) | Recipe of soothing liver and harmonizing stomach |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: LONGXI ZHONGTIAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LANZHOU UNIVERSITY Effective date: 20110331 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 730000 NO. 199 (SCHOOL OF MEDICINE, LANZHOU UNIVERSITY), DONGGANG WEST ROAD, CHENGGUAN DISTRICT, LANZHOU CITY, GANSU PROVINCE TO: 748100 CHANG'AN ROAD, LONGXI COUNTY, GANSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110331 Address after: 748100 Changan Road, Longxi County, Gansu Province Patentee after: LONGXI ZHONGTIAN PHARMACEUTICAL Co.,Ltd. Address before: Chengguan District of Gansu city of Lanzhou province Donggang West Road 730000 No. 199 (Lanzhou University Medical College) Patentee before: Lanzhou University |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20201211 Address after: 748100 North of Chang'an Road, Longxi County, Dingxi City, Gansu Province Patentee after: GANSU ZHONGTIAN JINDAN PHARMACEUTICAL Co.,Ltd. Address before: 748100 Chang'an Road, Longxi County, Gansu Province Patentee before: LONGXI ZHONGTIAN PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090729 Termination date: 20220124 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |